Parkinson’s Disease – Global Drug Forecast and Market Analysis to 2029

The Parkinson’s disease (PD) market is expected to see significant growth in the 7MM*, with the decade starting 2019 seeing an impressive 12.6% compound annual growth rate (CAGR), according to GlobalData. The leading data and analytics company notes that this growth is largely driven by the launch of 17 new pipeline products, which are set to address key unmet needs in the space. However, these will come at a higher cost compared to the currently marketed products, fueling market growth. The market is expected to rise from $3.5bn in 2019 to $11.5bn in 2029.

Sarah Elsayed, Neurology Analyst at GlobalData, comments: “The PD market is highly competitive, featuring many levodopa-combination therapies and adjunctive drug classes that aim to alleviate motor symptoms. However, these current treatment options are primarily symptomatic, off-patent, and not very effective in controlling the motor fluctuations that occur in advanced-stage patients.

“As a result, there are key unmet needs for drugs that have improved efficacy and delivery systems, and that provide disease-modifying benefits. New pipeline agents will aim to address some of these unmet needs and will have higher costs compared to the marketed products, which will fuel the growth of the PD market.”

Leading development strategies in PD across the pipeline mainly include the development of novel targets with potential disease-modifying properties and drug reformulations with innovative delivery systems.

Elsayed continues: “GlobalData anticipates that the most promising pipeline product will be Roche/Prothena’s PRX-002 (prasinezumab), an anti-alpha synuclein monoclonal antibody (mAb) in Phase II development. This drug has shown to potentially halt disease progression in clinical trials. GlobalData forecasts that it will generate global sales of $2.1bn by 2029, achieving the blockbuster status by 2028.”

Several late-stage pipeline agents have innovative systems for delivering levodopa therapy. This includes Intec’s Accordion Pill (levodopa/carbidopa) and Amneal’s IPX203 (levodopa/carbidopa), which are delivered orally in a gastric-retentive capsule to prolong the absorption of levodopa. Conversely, AbbVie’s ABBV-951 (foslevodopa) and Mitsubishi’s ND-0612 (levodopa/carbidopa) are delivered subcutaneously using an external small pump that maintains a continuous and steady flow of levodopa throughout the day and night.

Elsayed adds: “These products are expected to create improved options for physicians to control complications that arise with the continued use of levodopa. Therefore, some of these products are set to gain strong market uptake. The most promising drug in this group is forecast to be AbbVie’s ABBV-951 with global sales of $673.8m by 2029.”

* 7MM: The US, France, Germany, Spain, Italy, the UK, and Japan.

Scope

• Overview of PD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
• Annualized PD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (early and advanced) forecast from 2019 to 2029.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PD therapy. The most promising candidates in Phase IIb and Phase III development are profiled.
• Analysis of the current and future market competition in the global PD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Questions Answered

• What are the key PD treatments in 2019?
• When will the late stage pipeline products launch, and how will it affect drug sales and the overall PD market in the 7MM?
• Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Key Highlights

Current treatments for both early and advanced stage patients focus on controlling the level of dopamine in the brain.

GlobalData’s anticipate that 17 late stage pipeline drugs will launch over the forecast period. These will begin address longstanding unmet needs and are expected to be the main driver of growth in the PD market across the 7MM.

Roche/Prothena’s, a monoclonal antibody, has a novel MOA in the PD market and, if approved, will be revolutionary with potential neuroprotective properties.

The unmet need for therapies for treating late stage complications, such as wearing off, dyskinesia, and psychosis will remain unmet in the 5EU and Japan.

Opportunities are expected for pharmaceutical companies to develop drugs which have novel MOAs; which have potential disease modifying properties.

Reasons to Buy

The report will enable you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global PD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.